Basit öğe kaydını göster

Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study

dc.contributor.authorBilir, Cemil
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorUçar, Mahmut
dc.contributor.authorBerk, Veli
dc.contributor.authorYıldız, Yaşar
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorİnanç İmamoğlu, Gökşen
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorArpacı, Erkan
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorKarcı, Ebru
dc.contributor.authorTemiz, Süleyman
dc.contributor.authorNayır, Erdinç
dc.contributor.authorOktay, Esin
dc.contributor.authorDal, Pınar
dc.contributor.authorPetekkaya, İbrahim
dc.contributor.authorVarım, Ceyhun
dc.contributor.authorCinemre, Hakan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:59Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:59Z
dc.date.issued2017en_US
dc.identifier.citationBilir, C., Yıldız, İ., Bilici, A., Uçar, M., Berk, V., Yıldız, Y. ... Cinemre, H. (2017). Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study. Cancer Investigation, 35(4), 248-255. https://dx.doi.org/10.1080/07357907.2017.1292518en_US
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.urihttps://dx.doi.org/10.1080/07357907.2017.1292518
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2119
dc.descriptionWOS: 000399505100004en_US
dc.descriptionPubMed ID: 28333566en_US
dc.description.abstractBackground: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Inc.en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectHemoglobinen_US
dc.subjectPredictiveen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSurvivalen_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.titleIs change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group studyen_US
dc.typearticleen_US
dc.relation.ispartofCancer Investigationen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume35en_US
dc.identifier.issue4en_US
dc.identifier.startpage248en_US
dc.identifier.endpage255en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1080/07357907.2017.1292518en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
Bilicii-Ahmet-2017.pdf
Boyut:
442.0Kb
Biçim:
PDF
Açıklama:
Tam Metin / Full Text
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster